Adynxx Inc
OTC:ADYX
Adynxx Inc
Research & Development
Adynxx Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adynxx Inc
OTC:ADYX
|
Research & Development
-$5.2m
|
CAGR 3-Years
-79%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-24%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Adynxx Inc
Glance View
Adynxx, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 6 full-time employees. The firm is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.
See Also
What is Adynxx Inc's Research & Development?
Research & Development
-5.2m
USD
Based on the financial report for Sep 30, 2019, Adynxx Inc's Research & Development amounts to -5.2m USD.
What is Adynxx Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-24%
The average annual Research & Development growth rates for Adynxx Inc have been -79% over the past three years , and -24% over the past ten years .
